Instituto Rosenbusch S.A (ROSE) Fair Value & Analysis

Healthcare · AR · Market cap 6.8B ARS

Below-average quality, and screening another 35% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (140.53 ARS). The favourable scenario is already priced in.
• Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
• A fairly wide model range (67.67 ARS to 140.53 ARS) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range 9.00 ARS – 380.00 ARS · fair‑value band 67.67 ARS – 140.53 ARS · the 160.00 ARS price screens above the 104.10 ARS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Instituto Rosenbusch S.A (ROSE) currently trades at 160.00 ARS, while our model-based Fair Value estimate is 104.10 ARS, implying the stock looks roughly 34.9% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Instituto Rosenbusch S.A generated revenue of 6.4B ARS at a net margin of -71.8%. Revenue declined 10.5% year over year. Net debt stands at 738M ARS. Fundamentals as of Jul 19, 2026

Our scenario range runs from 67.67 ARS (bear case) to 140.53 ARS (bull case); at 160.00 ARS, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high and 38% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -35%, ROSE screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (223.60 ARS) versus Dividend Discount (11.71 ARS). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and …

Full company description

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals. The company was founded in 1917 and is based in Buenos Aires, Argentina.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Instituto Rosenbusch S.A reported revenue of 6.4B ARS in FY2025 versus 782M ARS in FY2021, a compound +69.2%/yr. Reported net income was −4.6B ARS in FY2025.

ROSE screens 35% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 624 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.